Budicort
Nebuliser Suspension
Generic Name
Budesonide
Manufacturer
Incepta Pharmaceuticals Ltd.
Unit Price
2 ml ampoule: ৳ 45.00 (2 x 6: ৳ 540.00)
🔹 Indications
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
🔹 Pharmacology
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
🔹 Dosage & Administration
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
🔹 Interaction
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
🔹 Contraindications
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
🔹 Side Effects
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
🔹 Pregnancy & Lactation
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
🔹 Precautions & Warnings
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
🔹 Pediatric Usage
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
🔹 Storage Conditions
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica) in which hospitalisation is indicated.
💡 Frequently Asked Questions
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica)...
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica)...
Budicort nebuliser suspension is indicated for the treatment of persistent bronchial asthma in patients where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. Very serious pseudocroup (laryngitis subglottica)...
User Reviews
⭐
No reviews yet!
Be the first to share your experience.